OncoMatch/Clinical Trials/NCT07132684
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Is NCT07132684 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Daunorubicin/Idarubicin and Cytarabine for aml, adult.
Treatment: Daunorubicin/Idarubicin · Cytarabine · Azacitidine · Venetoclax — This study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in elderly patients (aged 55-75) with acute myeloid leukemia (AML) who are fit for intensive chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: PML fusion with RARA
Acute promyelocytic leukemia with PML-RARA fusion gene
Excluded: RUNX1 fusion with RUNX1T1
AML with RUNX1-RUNX1T1 fusion gene
Excluded: CBFB fusion with MYH11
AML with CBFB-MYH11 fusion gene
Excluded: BCR fusion with ABL
AML with BCR-ABL fusion gene
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: induction chemotherapy
Exception: hydroxyurea is allowed
Relapsed or refractory AML (previously treated with induction chemotherapy, but hydroxyurea is allowed)
Lab requirements
Kidney function
Serum creatinine <2× ULN
Liver function
Total bilirubin ≤1.5× ULN; AST and ALT ≤2.5× ULN
Cardiac function
Cardiac enzymes <2× ULN; LVEF within normal range (by echocardiogram)
Adequate organ function: Total bilirubin ≤1.5× ULN; AST and ALT ≤2.5× ULN; Serum creatinine <2× ULN; Cardiac enzymes <2× ULN; LVEF within normal range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07132684 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with PML alterations eligible?
No. PML fusion with RARA is an exclusion criterion.
Are patients with RUNX1 alterations eligible?
No. RUNX1 fusion with RUNX1T1 is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 55 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages